OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SNDL$1.4659

SNDL Inc

PharmaceuticalsVerified

SNDL Inc's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage profile. The company maintains a strong liquidity position with a current ratio of 4.88 and cash and equivalents of CAD 252.24 million, which supports its operations and provides a buffer against short-term obligations. The price-to-book ratio of 0.34 suggests that the company is trading at a significant discount to its book value, potentially indicating undervaluation or underlying operational challenges. Profitability metrics for SNDL Inc are weak, with a negative return on equity of -1.43% and a negative return on assets of -1.18%. These figures are below the typical thresholds for profitability in the pharmaceuticals industry, which often emphasizes high returns on invested capital. The company reported a net loss of CAD 15.77 million and an operating loss of CAD 7.99 million, highlighting ongoing financial difficulties. Gross profit of CAD 258.65 million represents a margin of approximately 27.3%, which is relatively high for a cannabis company but insufficient to offset operating expenses. Geographically, SNDL Inc's revenue is primarily concentrated in Canada, where it operates under the legal cannabis framework. The company's exposure to the Canadian market is both a strength and a risk, as regulatory changes and market saturation could significantly impact its revenue. The company does not disclose detailed segment data, but its operations are largely focused on cannabis cultivation, production, and retail. The company's growth trajectory is mixed. While it has a strong cash position and positive operating cash flow of CAD 70.92 million, it has reported declining revenue and profitability. The outlook for the current fiscal year is uncertain, with no clear indication of a turnaround in earnings. The company's free cash flow of CAD 27.69 million and capital expenditure of CAD -12.81 million suggest that it is investing in its operations but not at a level that would significantly expand capacity or market share. Risk factors for SNDL Inc include the volatility of the cannabis market, regulatory changes, and competition. The company's liquidity risk is low, and there are no immediate filing-based liquidity or dilution flags. However, the company's negative net income and operating income indicate financial stress. The dilution risk is also low, with no significant dilution potential identified in the basic shares outstanding. Recent events include the company's continued focus on cost management and operational efficiency. SNDL Inc has been working to streamline its operations and reduce costs to improve profitability. The company's recent financial filings and investor relations communications highlight these efforts, but there is no indication of a significant shift in strategy or a major new product launch.

30-day price · SNDL(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanySNDL Inc
TickerSNDL.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. SNDL Inc is a Canadian cannabis company that cultivates, produces, and sells cannabis and cannabis-derived products for medical and recreational use.

Classification. SNDL Inc is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

SNDL Inc's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage profile. The company maintains a strong liquidity position with a current ratio of 4.88 and cash and equivalents of CAD 252.24 million, which supports its operations and provides a buffer against short-term obligations. The price-to-book ratio of 0.34 suggests that the company is trading at a significant discount to its book value, potentially indicating undervaluation or underlying operational challenges. Profitability metrics for SNDL Inc are weak, with a negative return on equity of -1.43% and a negative return on assets of -1.18%. These figures are below the typical thresholds for profitability in the pharmaceuticals industry, which often emphasizes high returns on invested capital. The company reported a net loss of CAD 15.77 million and an operating loss of CAD 7.99 million, highlighting ongoing financial difficulties. Gross profit of CAD 258.65 million represents a margin of approximately 27.3%, which is relatively high for a cannabis company but insufficient to offset operating expenses. Geographically, SNDL Inc's revenue is primarily concentrated in Canada, where it operates under the legal cannabis framework. The company's exposure to the Canadian market is both a strength and a risk, as regulatory changes and market saturation could significantly impact its revenue. The company does not disclose detailed segment data, but its operations are largely focused on cannabis cultivation, production, and retail. The company's growth trajectory is mixed. While it has a strong cash position and positive operating cash flow of CAD 70.92 million, it has reported declining revenue and profitability. The outlook for the current fiscal year is uncertain, with no clear indication of a turnaround in earnings. The company's free cash flow of CAD 27.69 million and capital expenditure of CAD -12.81 million suggest that it is investing in its operations but not at a level that would significantly expand capacity or market share. Risk factors for SNDL Inc include the volatility of the cannabis market, regulatory changes, and competition. The company's liquidity risk is low, and there are no immediate filing-based liquidity or dilution flags. However, the company's negative net income and operating income indicate financial stress. The dilution risk is also low, with no significant dilution potential identified in the basic shares outstanding. Recent events include the company's continued focus on cost management and operational efficiency. SNDL Inc has been working to streamline its operations and reduce costs to improve profitability. The company's recent financial filings and investor relations communications highlight these efforts, but there is no indication of a significant shift in strategy or a major new product launch.
Key takeaways
  • SNDL Inc has a strong liquidity position with a current ratio of 4.88 and significant cash reserves.
  • The company is trading at a significant discount to its book value, as indicated by a price-to-book ratio of 0.34.
  • SNDL Inc is experiencing financial difficulties, with a negative return on equity and operating loss.
  • The company's revenue is primarily concentrated in Canada, exposing it to regulatory and market risks.
  • The company's growth trajectory is uncertain, with no clear indication of a turnaround in earnings.
  • Risk factors include market volatility, regulatory changes, and competition, but liquidity and dilution risks are currently low.
  • # RATIONALES
  • {
Financial snapshot
PeriodHA-latest
CurrencyCAD
Revenue$946.4M
Gross profit$258.6M
Operating income-$8.0M
Net income-$15.8M
R&D
SG&A
D&A
SBC
Operating cash flow$70.9M
CapEx-$12.8M
Free cash flow$27.7M
Total assets$1.34B
Total liabilities$234.7M
Total equity$1.10B
Cash & equivalents$252.2M
Long-term debt$169.9M
Valuation
Market price$1.46
Market cap$379.8M
Enterprise value$297.5M
P/E
Reported non-GAAP P/E
EV/Revenue0.3
EV/Op income
EV/OCF4.2
P/B0.3
P/Tangible book0.3
Tangible book$1.10B
Net cash$82.3M
Current ratio4.9
Debt/Equity0.1
ROA-1.2%
ROE-1.4%
Cash conversion-4.5%
CapEx/Revenue-1.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricSNDLActivity
Op margin-0.8%7.7% medp25 -2.4% · p75 15.5%below median
Net margin-1.7%5.9% medp25 -3.8% · p75 12.8%below median
Gross margin27.3%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-1.4%-7.0% medp25 -14.9% · p75 -3.2%top quartile
Debt / equity15.0%25.0% medp25 3.8% · p75 63.3%below median
Observations
IR observations
Mean price target5.60 CAD
Median price target5.60 CAD
High price target6.20 CAD
Low price target5.00 CAD
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.20 CAD
Last actual EPS-0.04 CAD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 12:57 UTC#00f0439f
Market quoteclose CAD 1.44 · shares 0.26B diluted
no public URL
2026-05-16 12:59 UTC#23e1fc82
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 12:08 UTCJob: a5687661